Cardiac vasoplegia syndrome: Pathophysiology, risk factors and treatment

American Journal of the Medical Sciences

Volumn 349, Issue 1, 2015, Pages 80-88

  Omar, Sabry ^a   Zedan, Ahmed ^a   Nugent, Kenneth ^a  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER SCHOOL OF MEDICINE   (United States)

Author keywords

Cardiopulmonary bypass; Methylene blue; Vasoplegia; Vasopressin

Indexed keywords

DOPAMINE; METHYLENE BLUE; NORADRENALIN; PHENYLEPHRINE; TERLIPRESSIN; VASOPRESSIN; ANTIINFLAMMATORY AGENT; CATECHOLAMINE; CORTICOSTEROID; VASOCONSTRICTOR AGENT;

HUMAN; PATHOPHYSIOLOGY; PROGNOSIS; REVIEW; RISK FACTOR; VASOPLEGIA; VASOPRESSIN BLOOD LEVEL; CARDIOPULMONARY BYPASS; HEART DISEASES;

ADRENAL CORTEX HORMONES; ANTI-INFLAMMATORY AGENTS; CARDIOPULMONARY BYPASS; CATECHOLAMINES; HEART DISEASES; HUMANS; PROGNOSIS; RISK FACTORS; VASOCONSTRICTOR AGENTS; VASOPLEGIA;

EID: 84927916044     PISSN: 00029629     EISSN: 15382990     Source Type: Journal    
DOI: 10.1097/maj.0000000000000341     Document Type: Review

References (60)

1. Byrne JG, Leacche M, Paul S, et al. Risk factors and outcomes for "vasoplegia syndrome" following cardiac transplantation. Eur J Cardiothoracic Surg 2004;25:327-32.
2. Gomes WJ, Carvalho AC, Palma JH, et al. Vasoplegic syndrome after open heart surgery. J Cardiovasc Surg (Torino) 1998;39:619-23.
3. Leyh RG, Kofidis T, Struber M, et al. Methylene blue: the drug of choice for catecholamine-refractory vasoplegia after cardiopulmonary bypass? J Thorac Cardiovasc Surg 2003;125:1426-31.
4. Ozal E, Kuralay E, Yildirim V, et al. Preoperative methylene blue administration in patients at high risk for vasoplegic syndrome during cardiac surgery. Ann Thorac Surg 2005;79:1615-9.
5. Blackstone EH, Kirklin JW, Stewart RW, et al. The damaging effects of cardiopulmonary bypass. In: Wu KK, Roxy EC, editors. Prostaglandins in Clinical Medicine: Cardiovascular and Thrombotic Disorders. Chicago, IL: Year Book: 1982. p. 355.
6. Brash JL, Scott CF, Hove P, et al. Mechanism of transient adsorption of fibrinogen from plasma to solid surfaces: role of the contact and fibrinolytic systems. Blood 1988;71:932.
7. Lindon JN, McManama G, Kushner L, et al. Does the conformation of adsorbed fibrinogen dictate platelet interactions with artificial surfaces? Blood 1986;68:355.
8. Rinder CA, Rinder HM, Smith BR, et al. Blockade of C5a and C5b-9 generation inhibits leukocyte and platelet activation during extracorporeal circulation. J Clin Invest 1995;96:1564-72.
9. Wachtfogel YT, Kucich U, Greenplate J, et al. Human neutrophil degranulation during extracorporeal circulation. Blood 1987;69:324-30.
10. Kappelmeyer J, Bernabei A, Gikakis N, et al. Upregulation of Mac-1 surface expression on neutrophils during simulated extracorporeal circulation. J Lab Clin Med 1993;121:118-26.
11. Abrams CS, Ellison N, Budzynski AZ, et al. Direct detection of activated platelets and platelet-derived microparticles in humans. Blood 1990;75:128-38.
12. Lefkovits J, Plow EF, Topol EJ. Platelet glycoprotein Iib/IIIa receptors in cardiovascular medicine. N Engl J Med 1995;332:1553-9.
13. Rinder CS, Bonnert J, Rinder HM, et al. Platelet activation and aggregation during cardiopulmonary bypass. Anesthesiology 1991;74: 388-93.
14. Downing SW, Edmunds LH Jr. Release of vasoactive substance during cardiopulmonary bypass. Ann Thorac Surg 1992;54:1236.
15. Wan S, LeClerc J-L, Vincent J-L. Cytokine responses to cardiopulmonary bypass: lessons learned from cardiac transplantation. Ann Thorac Surg 1997;63:269-76.
16. Lasocki S, Provenchere S, Benessiano J, et al. Cardiac troponin I is an independent predictor of in-hospital death after adult cardiac surgery. Anesthesiology 2002;97:405-11.
17. Kerbaul F, Guidon C, Lejeune PJ, et al. Hyperprocalcitonemia is related to noninfectious postoperative severe systemic inflammatory response syndrome associated with cardiovascular dysfunction after coronary artery bypass graft surgery. J Cardiothorac Vasc Anesth 2002;161:47-53.
18. Hennein HA, Ebba H, Rodriguez JL, et al. Relationship of the proinflammatory cytokines to myocardial ischemia and dysfunction after uncomplicated coronary revascularization. J Thorac Cardiovasc Surg 1994;108:626-35.
19. Jochberger S, Velik-Salchner C, Mayr VD, et al. The vasopressin and copeptin response in patients with vasodilatory shock after cardiac surgery: a prospective, controlled study. Intensive Care Med 2009;35: 489-97.
20. Reid IA. Role of vasopressin deficiency in the vasodilation of septic shock. Circulation 1997;95:1108-10.
21. Landry DW, Levin HR, Gallant EM, et al. Vasopressin deficiency contributes to the vasodilation of septic shock. Circulation 1998;98:187.
22. Surks HK, Mochizuki N, Kasai Y, et al, Regulation of myosin phosphatase by a specific interaction with cGMP-dependent protein kinase I alpha. Science 1999;286:1583-7.
23. Levin MA, Lin HM, Castillo JG, et al. Early on-cardiopulmonary bypass hypotension and other factors associated with vasoplegic syndrome. Circulation 2009;120:1664-71.
24. Kortekaas KA, Lindeman JH, Reinders ME, et al. Pre-existing endothelial cell activation predicts vasoplegia after mitral valve surgery. Interact Cardiovasc Thorac Surg 2013;17:523-31.
25. Kerbaul F, Collart F, Giorgi R, et al. Role of endogenous adenosine as a predictive marker of vasoplegia during cardiopulmonary bypass and postoperative severe systemic inflammatory response. Crit Care Med 2006;34:640-5.
26. Nee L, Giorgi R, Garibaldi V, et al. Ischemia-modified albumin and adenosine plasma concentrations are associated with severe systemic inflammatory response syndrome after cardiopulmonary bypass. J Crit Care 2013;28:747-55.
27. Sun X, Zhang L, Hill PC, et al. Is incidence of postoperative vasoplegic syndrome different between off-pump and on-pump coronary artery bypass grafting surgery? Eur J Cardiothorac Surg 2008;34:820-5.
28. Patarroyo M, Simbaqueba C, Shrestha K, et al. Pre-operative risk factors and clinical outcomes associated with vasoplegia in recipients of orthotopic heart transplantation in the contemporary era. J Heart Lung Transpl 2012;31:282-7.
29. Colson PH, Bernard C, Struck J, et al. Post cardiac surgery vasoplegia is associated with high preoperative copeptin plasma concentration. Crit Care 2011;15:R255.
30. Carrel T, Englberger L, Mohacsi P, et al. Low systemic vascular resistance after cardiopulmonary bypass: incidence, etiology, and clinical importance. J Card Surg 2000;15:347-53.
31. Kao C-H, Lin C-Y, Lu C-W, et al. Vasoplegia syndrome is not associated with higher mortality rate after heart transplant. Acta Cardiol Sin 2012;28:129-36.
32. Mekontso-Dessap A, Houël R, Soustelle C, et al. Risk factors for postcardiopulmonary bypass vasoplegia in patients with preserved left ventricular function. Ann Thorac Surg 2001;71:1428-32.
33. Fischer GW, Levin MA. Vasoplegia during cardiac surgery: current concepts and management. Semin Thorac Surg 2010;22:140-4.
34. Kerbaul F, Bénard F, Giorgi R, et al. Adenosine A2A receptor hyperexpression in patients with severe SIRS after CBP. J Investig Med 2008; 56:864-71.
35. Sun X, Boyce SW, Herr DL, et al. Is vasoplegic syndrome more prevalent with open-heart procedures compared with isolated on-pump CABG surgery? Cardiovasc Revasc Med 2011;12:203-9.
36. Gomes WJ, Erlichman MR, Batista-Filho ML, et al. Vasoplegic syndrome after open heart surgery. J Cardiovasc Surg (Torino) 1998;39:619-23.
37. Levin RL, Degrange MA, Bruno GF, et al. Methylene blue reduces mortality and morbidity in vasoplegic patients after cardiac surgery. Ann Thorac Surg 2004;77:496-9.
38. Morales DL, Garrido MJ, Madigan JD, et al. A double-blind randomized trial: prophylactic vasopressin reduces hypotension after cardiopulmonary bypass. Ann Thorac Surg 2003;75:926-30.
39. Evora PR, Ribeiro PJ, de Andrade JC. Methylene blue administration in SIRS after cardiac operations. Ann Thorac Surg 1997;63:1212-13.
40. Argenziano M, Chen JM, Choudhri AF, et al. Management of vasodilatory shock after cardiac surgery: identification of predisposing factors and use of a novel pressor agent. J Thorac Cardiovasc Surg 1998;116:973-80.
41. Egi M, Bellomo R, Langenberg C, et al. Selecting a vasopressor drug for vasoplegic shock after adult cardiac surgery: a systematic literature review. Ann Thorac Surg 2007;83:715-23.
42. Landry DW, Oliver JA. The pathogenesis of vasodilatory shock. N Engl J Med 2001;345:588-95.
43. Holt NF, Haspel KL. Vasopressin: a review of therapeutic applications. J Cardiothorac Vasc Anesth 2010;24:330-47.
44. Papadopoulos G, Sintou E, Siminelakis S, et al. Perioperative infusion of low dose of vasopressin for prevention and management of vasodilatory vasoplegic syndrome in patients undergoing coronary artery bypass grafting- A double-blind randomized study. J Cardiothorac Surg 2010;5:17.
45. Noto A, Lentini S, Versaci A, et al. A retrospective analysis of terlipressin in bolus for the management of refractory vasoplegic hypotension after cardiac surgery. Interact Cardiovasc Thorac Surg 2009;9:588-92.
46. Weiner MM, Lin HM, Danforth D, et al. Methylene blue is associated with poor outcomes in vasoplegic shock. J Cardiothorac Vasc Anesth 2013;27:1233-8.
47. Agrawal A, Singh VK, Varma A, et al. Intravenous arginine vasopressin infusion in refractory vasodilatory shock: a clinical study. Indian J Pediatr 2012;79:488-93.
48. Russell JA, Walley KR, Singer J, et al. Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med 2008;358: 877-87.
49. Parillo JE. Septic shock-vasopressin, norepinephrine, and urgency. N Engl J Med 2008;358:954-6.
50. Riha H, Rihova L, Pindak M, et al. Methylene blue in the therapy of vasoplegic syndrome after cardiac surgery procedure. Cas Lek Cesk 2006;145:322-4.
51. Moncada S, Palmer RM, Higgs EA: Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev 1991;43:109-42.
52. Clifton J, Leikin J. Methylene blue. Am J Ther 2003;10:289-91.
53. Myles PS, Leong CK, Currey J. Endogenous nitric oxide and low systemic vascular resistance after cardiopulmonary bypass. J Cardiothorac Vasc Anesth 1997;11:571-4.
54. Beasley D, McGuiggin M. Interleukin 1 activates soluble guanylate cyclase in human vascular smooth muscle cells through a novel nitric oxide-independent pathway. J Exp Med 1994;179:71-80.
55. Schmidt HH. NO, CO and OH. Endogenous soluble guanylyl cyclaseactivating factors. FEBS Lett 1992;307:102-7.
56. Scott DM, Cooper MG. Spurious pulse oximetry with intrauterine methylene blue injection. Anaesthesiol Intensive Care 1991;19:267-8.
57. Murphy GS, Whitlock RP, Gutsche JT, et al. Steroids for adult cardiac surgery with cardiopulmonary bypass: update on dose and key randomized trials. J Cardiothorac Vasc Anesth 2013;27:1053-9.
58. Teoh KH, Bradley CA, Gauldie J, et al. Steroid inhibition of cytokine-mediated vasodilation after warm heart surgery. Circulation 1995;92(suppl 9):II347-53.
59. Ho KM, Tan JA. Benefits and risks of corticosteroid prophylaxis in adult cardiac surgery: a dose-response meta-analysis. Circulation 2009; 119:1853-66.
60. Dieleman JM, Nierich AP, Rosseel PM, et al. Intraoperative highdose dexamethasone for cardiac surgery: a randomized controlled trial. JAMA 2012;308:1761-7.